The CASP6 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the MES-OV human ovarian endometrioid adenocarcinoma cell line, with targeted disruption of the CASP6 gene. The polyclonal format consists of a heterogeneous pool of cells harboring various loss-of-function alleles, providing a robust model for caspase-6 functional studies without clonal artifacts. Supplied as a ready-to-use polyclonal population, it is suitable for a range of apoptosis and cancer research applications.
MES-OV is an epithelial ovarian cancer cell line derived from a patient with ovarian endometrioid adenocarcinoma, representing a clinically relevant model for high-grade serous and endometrioid carcinomas. These cells display aberrant proliferation and dysregulated apoptotic signaling, making them valuable for studying cell death pathways in gynecological malignancies. The parental line retains key oncogenic features, allowing assessment of how CASP6 loss influences tumor cell behavior and drug sensitivity.
CASP6 encodes the executioner caspase-6, which is activated by initiator caspases CASP8 and CASP10 (extrinsic pathway) and CASP9 (intrinsic pathway) and cleaves critical substrates including LMNA, PARP1, HTT, and DFFA to execute apoptosis. Its activity is regulated by IAPs such as XIAP and BIRC5, and it interacts with APAF1 in the apoptosome. Beyond cell death, caspase-6 participates in neurodegeneration signaling, linked to Alzheimer??s and Huntington??s diseases. Thus, CASP6 knockout disrupts executioner caspase activity, blocking apoptotic signaling and potentially modulating inflammatory pathways.
In MES-OV ovarian cancer cells, CASP6 knockout impairs apoptosis, providing a tool to investigate tumor cell evasion of programmed cell death and chemoresistance. Ovarian endometrioid adenocarcinomas often exhibit upregulated IAPs like XIAP and BIRC5, and this model allows dissection of their interplay with caspase-6. The polyclonal nature reflects diverse loss-of-function effects, enhancing translational relevance for studying how compromised executioner caspase function contributes to drug resistance and tumor-associated inflammation.
These knockout cells are suited for apoptosis mechanism studies, drug resistance screening, and neuroprotection assays. Researchers can perform western blotting for caspase-6 cleavage and substrate processing, caspase-6 activity assays, TUNEL assays, and flow cytometry for apoptosis. Cell viability assays following chemotherapeutic treatment enable drug sensitivity profiling. The model also supports inflammatory response studies via cytokine analysis. For further information or custom requests, please contact Ascent Research.
